Every Form 4 that Bristol-Myers Squibb Co. (BMY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BMY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMY filings page.
Bristol Myers Squibb EVP, General Counsel Cari Gallman reported that 4,559 restricted stock units vested and converted into 4,559 common shares on October 2, 2026. The units vested in three equal installments beginning October 2, 2024, and each unit converts into one common share upon vesting. Upon vesting, 2,332 common shares were withheld for taxes; the reported price was $61.15 per share.
Bristol Myers Squibb (BMY) director Phyllis R. Yale acquired 560.8970 Deferred Share Units on September 30, 2026. Her reported direct position after the acquisition was 45,980.0770 Deferred Share Units. Each unit converts into a share of common stock upon settlement; the units become settleable when she ceases to be a director or at a future date she previously specified. The units include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb (BMY) director Theodore R. Samuels II acquired 821.3140 Deferred Share Units on September 30, 2026. His resulting direct position was 71,859.0410 Deferred Share Units, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Each unit converts into a share of common stock upon settlement; the units become settleable when he ceases to be a director or on a future date he previously specified.
Bristol Myers Squibb director Derica W. Rice acquired 620.994 Deferred Share Units on September 30, 2026. Her reported direct balance after the transaction was 42,084.867 Deferred Share Units, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Each unit converts into one common share upon settlement, which becomes available when she ceases to be a director or at a future date she previously specified.
Bristol Myers Squibb director Michael R. McMullen acquired 560.8970 Deferred Share Units on September 30, 2026, bringing his reported balance to 17,050.6010 units. Each unit converts into one share of common stock upon settlement. The units become settleable when he ceases to be a director or at a future date he previously specified.
Bristol Myers Squibb director Peter J. Arduini acquired 560.897 Deferred Share Units on September 30, 2026, bringing his reported direct position to 74,077.176 units. Each unit converts into a share of common stock upon settlement. The reported position includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. No Rule 10b5-1 plan is reported.
BRISTOL MYERS SQUIBB CO (BMY) reported that executive officer Cristian Massacesi, EVP, Chief Medical Officer and Head of Development, sold 6,249 shares of common stock on September 9, 2026 in a sale described as an open market or private transaction at $64.57 per share. After this transaction, he directly holds 18,748 shares of Bristol Myers Squibb common stock, and no Rule 10b5-1 trading plan is reported.
Bristol Myers Squibb Co (BMY) reported that executive vice president of Corporate Affairs Wendy Bartie Short had 1,236 Restricted Stock Units vest and convert into an equal number of shares of common stock on September 1, 2026. The related RSU award was granted to vest in four equal installments beginning September 1, 2023.
Of the vested shares, 633 shares of common stock were withheld to pay tax liabilities at a reported value of $66.92 per share, leaving the remainder effectively delivered to her as directly owned common stock. Following the vesting, the underlying RSU derivative position reported on this form was reduced to zero.
BRISTOL MYERS SQUIBB CO (BMY) reported that Phil M. Holzer, its SVP and Controller, sold 500 shares of common stock on 2026-08-25 in a sale in open market or private transaction at a price of $67.50 per share. Following this transaction, Holzer directly holds 16,862 shares of BMY common stock. The filing indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan.
Bristol Myers Squibb executive Cristian Massacesi, EVP, Chief Medical Officer and Head of Development, reported the vesting and conversion of 51,172 restricted stock units into an equal number of common shares on August 1, 2026. To cover tax obligations, 26,175 shares were withheld at a per-share value of $65.31. Following the RSU conversion, Massacesi reported holding 153,519 restricted stock units, and these transactions were not designated as made under a Rule 10b5-1 trading plan.
Cari Gallman, EVP and General Counsel of Bristol Myers Squibb, reported equity compensation activity on August 1, 2026. 1,061 restricted stock units vested in three equal installments beginning on August 1, 2024, with each unit converting into one share of common stock. 543 shares of common stock were withheld at $65.31 per share to satisfy tax obligations upon vesting.
Bristol Myers Squibb director Phyllis R. Yale reported a routine compensation-related grant of deferred share units. On this Form 4, she acquired 607.428 Deferred Share Units, each economically valued at $57.62, tied to the company’s common stock. These units are part of a non-employee director compensation program and will be converted into common shares when she leaves the board or at a future date she previously selected.
Following this grant, Yale holds a total of 44,986.288 deferred share units, which also reflect deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors. This filing reflects a non-market, derivative award rather than an open-market stock purchase or sale.
Bristol Myers Squibb director Theodore R. Samuels II reported receiving an award of 889.448 Deferred Share Units on June 30, 2026. These units represent deferred compensation tied to the company’s common stock and are granted at a reference price of $57.62 per unit.
Each Deferred Share Unit will convert into one share of Bristol Myers Squibb common stock upon settlement. According to the terms, settlement occurs when Samuels ceases to be a director or at a future date he previously selected. After this grant and related deferred amounts and reinvested dividends, he now holds a total of 70,360.664 Deferred Share Units directly.
Bristol Myers Squibb director Derica W. Rice received a grant of deferred share units as part of non-employee director compensation. On this Form 4, Rice was awarded 672.5100 Deferred Share Units at a reference price of $57.6200 per unit, increasing her direct holdings of these units to 41,068.6810. Each unit is designed to convert into one share of common stock upon settlement, which occurs when she ceases to be a director or at a future date she previously selected. The position also reflects deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors, making this a routine, compensation-related equity accrual rather than an open-market trade.
Bristol Myers Squibb director Michael R. McMullen received a grant of 607.428 Deferred Share Units, each valued at $57.62. These units represent deferred compensation that will be converted into common stock when he ceases to be a director or at a previously chosen future date.
Following this award, McMullen holds a total of 16,332.540 Deferred Share Units tied to Bristol Myers Squibb common stock, including prior deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. This filing reflects a compensation-related equity award rather than an open-market stock purchase or sale.
Bristol Myers Squibb director Peter J. Arduini received a grant of deferred share units tied to company stock. He acquired 607.428 Deferred Share Units at an assigned value of $57.62 per unit, each corresponding to one share of common stock.
These units will convert into common stock when he ceases to be a director or on a future date he previously selected. Following this grant, his deferred share unit balance is 72,815.595, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Julia A. Haller exercised stock options to acquire 20,460 shares of common stock at $53.76 per share. The transaction on June 15, 2026 was a cash exercise, and she is holding all of the underlying shares.
Following this exercise, Haller directly owns 34,079 shares of Bristol Myers Squibb common stock, and the option covering these 20,460 shares has been fully exercised with no remaining balance.
Bristol Myers Squibb executive Wendy Short Bartie, EVP of Corporate Affairs, reported routine equity compensation transactions involving restricted stock units. She exercised 8,040 restricted stock units, each converting into one share of common stock, and a portion of the resulting shares was used to cover taxes.
The filing shows a tax-withholding disposition of 3,876 common shares at $54.72 per share to satisfy tax obligations upon vesting, not an open-market sale. After these transactions, she directly holds 12,081 shares of common stock. The restricted stock units vest annually in three equal installments beginning on June 3, 2025, and were scheduled compensation rather than discretionary trading.
Bristol Myers Squibb EVP and Chief Commercial Officer Adam Lenkowsky reported routine equity award activity involving market share units and common stock. On May 1, 2026, he exercised 1,373 market share units into common stock and recorded related adjustments tied to performance factors.
The filing shows 599 common shares were withheld at $58.22 per share to cover taxes upon vesting, which is not an open-market sale. An additional 203 shares were moved in an "other" transaction. Following these changes, he directly holds 19,706 common shares, plus indirect holdings through a spouse and a BMS savings plan.
Bristol Myers Squibb executive Karin Shanahan, EVP and Chief Supply Chain & Ops, exercised 3,307 restricted stock units into an equal number of common shares. The units vested in four equal annual installments beginning on April 1, 2023, with each unit converting into one share.
Upon vesting, 1,692 shares of common stock were withheld at $61.73 per share to cover taxes, a non–open-market, tax-withholding disposition. After these transactions, Shanahan holds 25,888 common shares directly and 1,457.74 shares indirectly through the BMS Savings and Investment Program.
Bristol Myers Squibb EVP and CFO David V. Elkins reported open-market sales of company stock. On April 1, 2026, he sold 25,519 shares of common stock at a weighted average price of $61.60 per share and 4,481 shares at $62.05 per share, totaling 30,000 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the sales, he directly held 159,248 shares of Bristol Myers Squibb common stock and had an additional 294.42 shares held indirectly through the BMS Savings and Investment Program, based on a recent 401(k) plan statement.
Bristol Myers Squibb director Phyllis R. Yale received 577.082 Deferred Share Units as a compensation award. The grant was valued at $60.65 per unit and is linked to an equal number of underlying common shares. Following this award, she holds 43,903.777 Deferred Share Units in total.
The units will convert into common stock when she leaves the board or on a future date she previously chose. Her balance includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II received a grant of 845.012 Deferred Share Units as compensation. These units are tied to Bristol Myers Squibb common stock at a reference price of $60.65 per unit.
Each Deferred Share Unit converts into one share of common stock when his board service ends or on a future date he previously selected. Following this award, he holds a total of 68,727.516 Deferred Share Units, which also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Derica W. Rice received a grant of 638.912 Deferred Share Units on common stock. The award is classified as a grant or other acquisition, not an open-market purchase or sale. Each unit will convert into one share of common stock upon settlement.
The Deferred Share Units become settleable when Rice ceases to be a director or at a future date previously specified. Following this grant, Rice holds a total of 39,963.721 Deferred Share Units, which include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Michael R. McMullen received a grant of Deferred Share Units as board compensation. On March 31, 2026, he was awarded 577.082 Deferred Share Units, with a reference price of $60.65 per unit.
Each unit will convert into one share of common stock upon settlement, which occurs when he ceases to be a director or on a future date he previously selected. After this award, he holds 15,556.771 Deferred Share Units, including deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Peter J. Arduini received a grant of 577.082 Deferred Share Units, each tied to common stock valued at $60.65 per unit. After this compensation award, he directly holds a total of 71,435.166 Deferred Share Units.
Each Deferred Share Unit will convert into one share of common stock when the units are settled. Settlement occurs when Arduini ceases to be a director or on a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb reported that Benjamin Hickey, President of the RayzeBio organization, received equity-based awards on March 10, 2026. He was granted 11,429 market share units and 17,143 performance shares, each tied to Bristol Myers Squibb common stock.
Each market share unit converts into shares based on a payout factor linked to total shareholder return, with a minimum payout factor of 80% and a maximum of 225%. These market share units cliff vest on the third anniversary of the grant date, subject to Board certification of performance. Each performance share converts into one share of common stock upon distribution in the first quarter of 2029, also subject to Board certification of performance results.
Bristol Myers Squibb executive Hiroshi Chris Shibutani, EVP and Chief Strategy Officer, received equity-based compensation awards in the form of derivatives tied to the company’s common stock. On March 10, 2026, he was granted 7,837 Market Share Units and 11,755 Performance Shares at a price of $0.00 per unit.
Each market share unit represents a target number of shares that can convert into common stock based on a payout factor linked to total shareholder return and a relative TSR floor, with a minimum payout factor of 80% and a maximum of 225%. These market share units cliff vest on the third anniversary of the grant date, subject to the Board certifying performance results, and carry an expiration date of March 10, 2029.
Each performance share converts into one share of common stock upon distribution in the first quarter of 2029, also subject to certification of performance results by the Board. After these grants, reported holdings for these awards are 7,837 market share units and 11,755 performance shares, respectively.
Massacesi Cristian reported acquisition or exercise transactions in this Form 4 filing.
Bristol Myers Squibb executive Cristian Massacesi received new performance-based equity awards. On March 10, 2026, he was granted 26,122 Market Share Units and 39,184 Performance Shares, each tied to the company’s common stock. The Market Share Units cliff vest after three years, while payouts for both awards depend on Total Return and relative total shareholder return performance through around 2029.
Bristol Myers Squibb EVP Wendy Short Bartie reported multiple equity-related transactions in connection with long-term incentive awards. On March 10, 2026, she exercised market share units and performance shares, receiving a total of 5,883 shares of common stock through derivative conversions.
She also received new grants of 6,531 market share units and 9,796 performance share units that are subject to future performance certification and vesting, generally around 2029. To cover tax obligations upon vesting, 1,275 common shares were withheld at $60.13 per share.
After these transactions and related performance-based adjustments, she directly holds 7,917 shares of Bristol Myers Squibb common stock, in addition to the newly granted performance-based units. The filing reflects routine compensation vesting, new awards, and associated tax withholding rather than open-market buying or selling.
Bristol Myers Squibb executive Karin Shanahan reported multiple equity compensation transactions. On March 10, 2026, she exercised or converted derivative awards into 25,501 shares of common stock and received new grants of 21,224 market share units and 31,837 performance shares.
The filing shows 7,760 shares of common stock were withheld at $60.13 per share to cover tax obligations upon vesting. After these routine compensation-related events and adjustments, Shanahan directly held 24,273 shares of common stock and indirectly held 1,278.64 shares through the BMS Savings and Investment Program.
Bristol Myers Squibb executive vice president and chief research officer Robert M. Plenge reported multiple equity-compensation events in company stock. On March 10, 2026, prior market share units and performance shares vested and were exercised into a total of 17,501 shares of common stock, with 4,535 shares withheld at $60.13 per share to cover taxes.
Plenge also received new long-term incentives: 17,959 market share units and 26,939 performance share units scheduled to run to 2029, subject to performance certification by the board. Following these transactions, he holds 21,528 shares directly, plus indirect interests of 3,026.38 shares through the BMS Savings and Investment Program and 200 shares in a family trust. All actions reflect compensation vesting, internal adjustments, and tax withholding, with no open-market purchases or sales reported.
Bristol Myers Squibb executive Gregory Scott Meyers reported multiple equity award transactions. He exercised derivative awards covering 25,892 shares of common stock tied to vested market share units from 2022 and 2023 grants and performance shares earned under the 2023-2025 long-term performance award.
The company withheld 6,582 shares at $60.13 per share to cover tax liabilities upon vesting, which is not an open-market sale. Meyers also received new grants of 26,122 market share units and 39,184 performance share units that may convert into common stock based on future performance and Board certification. Following these transactions, he directly holds 30,361 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb executive Adam Lenkowsky reported multiple stock-based compensation events involving common stock and performance-linked awards. On March 10, 2026, he exercised or settled derivative awards covering 24,071 shares tied to market share units and performance shares, with no open‑market purchases or sales.
The filing shows 7,015 common shares withheld at $60.13 per share to satisfy tax obligations as awards vested. Lenkowsky also received new long-term incentives, including 32,653 market share units and 48,980 performance share units scheduled to run to 2029, all linked to Bristol Myers Squibb common stock.
After these transactions, he directly holds 19,135 shares of common stock, plus indirect holdings of 5,849.47 shares through a BMS savings and investment program and 2,929 shares held by his spouse. Footnotes clarify these events reflect routine vesting, performance adjustments, and tax withholding under the company’s long-term incentive plans.
Bristol Myers Squibb SVP and Controller Phil M. Holzer reported multiple equity award transactions in company stock and units on March 10, 2026. He exercised market share units and performance shares covering 6,191 shares of common stock and received new grants of 5,031 market share units and 7,547 performance share units under long-term incentive programs.
The filing shows vesting and performance-based adjustments to prior awards, along with 1,358 common shares withheld at $60.13 per share to cover tax obligations. Following these compensation-related transactions, Holzer directly holds 17,362 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb President, Cell Therapy Org. Lynelle Hoch reported multiple equity compensation transactions in company stock. On March 10, 2026, she exercised derivative awards, including market share units and performance shares, converting them into a total of 8,192 shares of common stock.
The filing also shows new grants of 6,531 market share units and 9,796 performance share units, each tied to future performance measurement periods and vesting dates through 2029. A total of 1,391 common shares were withheld at $60.13 per share to cover tax obligations upon vesting. Following these transactions, Hoch directly holds 8,210 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb executive Cari Gallman reported multiple equity-compensation transactions tied to prior and new long‑term incentive awards. On March 10, 2026, she exercised or converted derivative awards into a total of 6,980 shares of common stock, reflecting vesting of earlier market share units and performance shares granted in prior years.
The company withheld 2,165 shares at a price of $60.13 per share to cover tax obligations upon vesting, which is not an open‑market sale. Gallman also received new grants of 26,122 market share units and 39,184 performance share units that run through 2029, with payouts based on multi‑year stock price and performance formulas described in the award terms.
Bristol Myers Squibb executive vice president and chief people officer Amanda Poole Ahn reported several equity award events tied to performance-based compensation. On March 10, 2026, derivatives representing 6,436 shares of common stock were converted upon vesting of market share units and performance shares.
The company withheld 1,992 shares of common stock at $60.13 per share to cover tax obligations tied to these awards. Ahn also received new long-term incentives: 15,347 market share units and 23,020 performance share units, both scheduled to run to 2029 under performance-based payout structures.
Following these transactions, Ahn holds 7,094 shares of common stock directly and an additional 221.82 shares indirectly through the BMS Savings and Investment Program, reflecting routine compensation-related equity activity rather than open-market buying or selling.
Bristol Myers Squibb Chief Executive Officer Christopher S. Boerner reported multiple equity compensation transactions involving common stock and share units. On 2026-03-10, he exercised or settled 71,537 market share and performance share units into common stock and had 21,229 shares withheld at $60.13 per share to cover tax obligations and exercise costs.
He also received new long-term incentives, including 104,490 market share units and 156,735 performance share units that vest or convert based on multi-year performance conditions and Board certification. After these transactions, Boerner held 21,451 shares of common stock directly and 125,439 shares indirectly through a trust, reflecting compensation-related awards and routine tax withholding rather than open-market trading.
Bristol Myers Squibb EVP and CFO David V. Elkins reported a series of equity compensation transactions involving company stock. He exercised derivative awards, converting 62,982 market share units and performance shares into common stock on March 10, 2026, as previously granted awards vested under performance-based plans. He also received new grants of 35,265 market share units and 52,898 performance share units that will vest in future years based on performance and Board certification. To cover tax obligations on these vestings, 16,114 shares of common stock were withheld at a price of $60.13 per share, which is a non-market tax payment rather than an open-market sale. Following these transactions, Elkins directly holds 189,248 shares of common stock and has an additional 291.17 shares held indirectly through the BMS Savings and Investment Program.
Bristol Myers Squibb executive Benjamin Hickey, President of the RayzeBio organization, reported equity compensation activity involving restricted stock units and common stock. On February 27, 2026, 3,286 restricted stock units were exercised or converted into 3,286 shares of common stock at $0.00 per share as they vested. In connection with this vesting, 1,672 common shares were withheld at $62.37 per share to cover tax obligations, a non‑open‑market disposition. After these transactions, Hickey directly held 16,672 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb executive Gregory Scott Meyers reported equity compensation activity involving restricted stock units and common shares. On February 1, 2026, 2,543 restricted stock units vested and converted into 2,543 shares of common stock at an exercise price of $0, reflecting previously granted awards that vest annually in four equal installments beginning on February 1, 2023.
On the same date, 833 common shares were withheld at a price of $55.05 to cover taxes due upon vesting of the restricted stock units. After these transactions, Meyers directly owned 21,428 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb executive Benjamin Hickey reported routine equity compensation activity. On February 1, 2026, 10,079 restricted stock units vested, each converting into one share of common stock at an exercise price of $0.
To cover taxes on the vesting, 3,810 common shares were withheld at a price of $55.05 per share. After these transactions, Hickey directly owned 15,058 shares of Bristol Myers Squibb common stock and 10,079 restricted stock units remained outstanding, scheduled to vest in equal annual installments beginning February 1, 2025.
Bristol Myers Squibb director Phyllis R. Yale received 3,996.367 Deferred Share Units on February 1, 2026 at a reference price of $55.05 per unit. These derivative awards increase her holdings of Deferred Share Units to 43,326.695, all held directly.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when she ceases to be a director or at a future date she previously specified, and reflect deferred compensation and reinvested dividends under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Karen H. Vousden reported an award of derivative securities tied to company stock. On February 1, 2026, she acquired 3,996.367 Deferred Share Units at $55.05 each, bringing her total to 41,069.315 Deferred Share Units, held directly.
Each Deferred Share Unit converts into one share of Bristol Myers Squibb common stock upon settlement. These units become settleable when she ceases to be a director or at a future date she previously selected. The total includes deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II reported an automatic grant of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. After this award, he beneficially owns 67,882.504 Deferred Share Units in total.
Each Deferred Share Unit converts into one share of common stock when settled. These units become settleable when he ceases to be a director or on a future date he previously selected, and the total includes deferred compensation and reinvested dividends under the company’s deferred compensation plan for non-employee directors.
Bristol Myers Squibb director Derica W. Rice reported an award of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. This increased his holdings of Deferred Share Units to 39,324.809, which track common stock and are settled in shares later.
Each Deferred Share Unit converts into one share of common stock when he leaves the board or on a future date he previously selected. The holdings also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Paula A. Price reported receiving 3,996.367 Deferred Share Units on February 1, 2026 at an indicated value of $55.05 per unit. Following this award, she beneficially owns 25,498.163 Deferred Share Units, held directly.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when Price ceases to be a director or at a future date she previously specified, and include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Michael R. McMullen reported an acquisition of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. Following this transaction, he beneficially owns 14,979.689 Deferred Share Units directly.
Each Deferred Share Unit will convert into one share of common stock upon settlement, which occurs when McMullen ceases to be a director or at a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Manuel Hidalgo Medina reported an award of 3,996.367 Deferred Share Units on common stock, effective February 1, 2026, at a reference price of $55.05 per unit. Following this grant, he holds 22,763.938 Deferred Share Units in total, all reported as directly owned.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. According to the disclosure, these units become settleable when he ceases to be a director or on a future date he previously specified. The total also reflects deferred compensation and dividends that have been reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.